65,437 trials
Rheumatoid Arthritis
Primary: Number of Participants With an Improvement in Bone Edema/Osteitis on Low-field MRI in Rheumatoid Arthritis Patients on Weekly SC Abatacept in Combination With…
Alzheimer's Disease
Primary: Memory Composite — -2.5; -2.8; -2.3; -2.8 units on a standardized scale
Prostate Cancer
Primary: Safety - Infection That Requires IV Antibiotics or Re-hospitalization — 0 Events
Spinal Muscular Atrophy
Primary: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs — 8; 6; 9; 9 Participants
Migraines
Primary: 2- Hour Pain Relief — 72.5; 69.4; 38.8 percentage of participants
Diabetes Mellitus, Type 2
Primary: Overall Decisional Comfort (0-100, 100=no Conflict) — 82; 75.1 units on a scale
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response After First Course — 67.1 percentage of participants
Breast Cancer
Primary: Change in the Percentage of Breast Epithelial Cells Expressing Ki-67, From Baseline to 6 Months — -3.0 percentage of positive cells — p=<0.001
Asthma
Primary: Number of Healthy and Asthmatic Participants With Events of Clinical Interest (ECI) (Part 1) — 1; 0; 0; 0 Participants
Plaque Psoriasis · Psoriatic Arthritis · Pustular Psoriasis (Excluding a Localized)
Primary: Percentage of Patients Achieving 75% Improvement in the Psoriasis Area and Severity Index (PASI) Score — 0.0; 0.0; 0.0; 0.0 percentage of participants
NSCLC (Non-small Cell Lung Cancer)
Primary: Progression-Free Survival (PFS) Based on IRR by Treatment Arm — 11.1; 6.8 Months — p=<0.0001
Alpha₁-Antitrypsin Deficiency
Primary: AUC(0-7 Days) Based on Antigenic Content — 203.20; 198.38 mg*h/mL
Poor Performance Status
Primary: Running Performance — 52.8; 52.8 minutes
Cutaneous Abscess
Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants
Osteoarthritis, Knee · Osteoarthritis, Hip
Primary: Change in Lower Extremity Function — 6.9; 0.5 Change in scores on a scale